In accordance with this hypothesis, it should be mentioned that in some other non-cancer experiments the therapeutic benefits of α7nAChR agonists were used to improve wound healing processes as well as in the treatment of neurodegenerative illnesses such as Parkinson's and Alzheimer's diseases [105]. This evidence concerns the gene CHRNA7 and early-onset autosomal dominant Alzheimer disease.